Fibronectin rescues aberrant phenotype of endothelial cells lacking either CCM1, CCM2 or CCM3
Konrad Schwefel, Stefanie Spiegler, Bettina C. Kirchmaier, Patricia K. E. Dellweg, Christiane D. Much, Jan Pané‐Farré, Tim M. Strom, Katharina Riedel, Ute Felbor, Matthias Rath
Abstract
Abstract Loss‐of‐function variants in CCM1/KRIT1 , CCM2 , and CCM3/PDCD10 are associated with autosomal dominant cerebral cavernous malformations (CCMs). CRISPR/Cas9‐mediated CCM3 inactivation in human endothelial cells (ECs) has been shown to induce profound defects in cell‐cell interaction as well as actin cytoskeleton organization. We here show that CCM3 inactivation impairs fibronectin expression and consequently leads to reduced fibers in the extracellular matrix. Despite the complexity and high molecular weight of fibronectin fibrils, our in vitro model allowed us to reveal that fibronectin supplementation restored aberrant spheroid formation as well as altered EC morphology, and suppressed actin stress fiber formation. Yet, fibronectin replacement neither enhanced the stability of tube‐like structures nor inhibited the survival advantage of CCM3 −/− ECs. Importantly, CRISPR/Cas9‐mediated introduction of biallelic loss‐of‐function variants into either CCM1 or CCM2 demonstrated that the impaired production of a functional fibronectin matrix is a common feature of CCM1‐, CCM2‐, and CCM3‐deficient ECs.